DRY COUGH : Rapid and Effective Relief for Cough Symptoms
DRY COUGH : A revolutionary 30ml throat spray designed to treat cough. Its filmogen liquid bandage formulation targets pro-inflammatory proteins and contaminants, providing a protective barrier, cleaning effect, and promoting cellular repair and growth. Clinical trials show significant reduction in cough severity, frequency, throat irritation, and pain within 12 days, with decreased need for antibiotics.
DRY COUGH by Vitrobio: A Revolutionary Approach to Cough Treatment
DRY COUGH is a groundbreaking product from Vitrobio, designed to provide a comprehensive solution for the treatment of cough. This product is a filmogen liquid bandage, presented as a 30ml throat spray, and is specifically formulated to combat both viral and bacterial throat infections that lead to coughing.
Targeted Proteins and Actions
The unique formulation of DRY COUGH targets pro-inflammatory proteins, contaminants, and impurities. Its mode of action is threefold:
Protective Barrier Effect: The filmogen liquid bandage acts as an absorbent barrier against incoming allergens and contaminants, providing immediate protection to the nasal mucosa.
Osmotic and Cleaning Effect: The high osmotic activity of the product instantly attracts and traps most of the adhered contaminants, including inflammatory proteins and allergens. This suppresses inflammation and the immune cascade, providing immediate relief from symptoms.
Cellular Repair and Growth Effect: By creating a clean and hydrated biological surface, DRY COUGH immediately triggers cell growth and healing. This helps restore the integrity of the nasal mucosa, further alleviating symptoms and promoting recovery.
Clinical Study
The efficacy of DRY COUGH has been demonstrated in a randomized, double-blind, placebo-controlled trial over two weeks. The study included 54 patients, with 37 receiving the test product and 17 receiving the comparator. The results were impressive:
-
Antibiotics: The requirement for antibiotics was significantly reduced in the test group (10.81% of patients) compared to the placebo group (82.35%).
-
Severity: There was a 76% reduction in dry cough severity within 12 days.
-
Frequency: There was a 98% reduction in dry cough frequency within 14 days.
-
Throat Irritation: There was a 90% reduction in throat irritation within 12 days.
-
Throat Pain: There was a 99% reduction in throat pain within 14 days.
These results demonstrate the effectiveness of DRY COUGH in providing rapid and lasting relief from the symptoms of cough, while also reducing the need for antibiotics. No side effects were recorded, further attesting to the safety of the product.
For more detailed information on the clinical study, please refer to the full text of the published research.
DRY COUGH by Vitrobio represents a new era in cough treatment, offering a safe, effective, and rapid solution to alleviate the symptoms and address the underlying causes of cough.
Understanding Dry Cough: Causes, Diagnosis, and Treatment
The Nature of Dry Cough
Dry cough is a prevalent symptom that can be associated with diseases of various systems, including respiratory, cardiovascular, digestive, and endocrine. It is a reflex action triggered by the stimulation of cough receptors due to pathological influences. The nature of the cough, its duration, and the results of laboratory and instrumental examination methods are all taken into account during diagnosis.
Chronic Cough: A Cause for Concern
Chronic cough requires particular attention to exclude life-threatening causes. Symptoms that raise concern include hemoptysis (coughing up blood), prolonged resistant cough, extended intoxication syndrome, and weight loss. In diagnostically unclear cases, the examination schedule must include computed tomography of the chest, magnetic resonance imaging, and bronchoscopy.
The Impact of Intense Dry Cough
An intense, painful dry cough can lead to complications such as a decrease in quality of life, hemorrhages, and pneumothorax. Therefore, it necessitates symptomatic treatment. Common causes of unproductive cough include viral diseases, whooping cough, and diseases leading to overactive cough receptors.
A Differentiated Approach to Cough Therapy
The variety of coughs necessitates a differentiated approach to its therapy. The primary efforts should be directed towards the treatment of the underlying disease. In the case of a productive cough, mucoactive drugs are used. To stop unproductive cough, antitussive drugs of central and peripheral action are used.
Dry Cough and COVID-19
In the case of COVID-19, symptoms include fever, dry cough, body aches, and anosmia (loss of smell). The continuous triggering of the innate and acquired immune system, as well as the overproduction of pro-inflammatory factors, can lead to a severe condition in COVID-19 patients, known as a « cytokine storm ». This can result in acute respiratory distress syndrome (ARDS) in critical patients. Severe and critical COVID-19 cases require oxygen therapy and mechanical ventilator support.
The Importance of Professional Consultation
It is crucial to consult a healthcare professional for a proper diagnosis and treatment of dry cough. Self-diagnosis or treatment can lead to complications and should be avoided.
CLAIMS IN LINE WITH THE NEW REGULATION
- Mechanical mode of action
- Instant osmotic action
- Hydrates, protects and cleanses
- Dual action: Soothes and treats
- Reduces contaminants on the throat surface
- Reduces cough severity, intensity and frequency
- Reduces pain, irritation, redness and swelling
- Reduces swallowing difficulties
- Reduces the need for antibiotics
- Effects felt after 2 hours
- No drowsiness
- Non addictive
« DRY COUGH by Vitrobio: Rapid and Effective Relief for Cough Symptoms »
General informations
Title : Clinical Efficacy of Novel Filmogen, Antimicrobial, Cleaning, Fluidizing Cough
Treatment
Journal : Clinical Trials | 2017
Patients: N=54 | Test product = 37 ; Comparator = 17
Duration : 2 weeks
Inclusion : Suffering from dry cough
Link to the publication
Main results
ANTIBIOTICS
Requirements for antibiotics strongly diminished in the test group (10.81 % patients) vs placebo group (82.35 %)
SEVERITY
15,81 % reduction in dry cough severity within 2 days.
32,08 % reduction in dry cough severity within 3 days.
46,39 % reduction in dry cough severity within 6 days.
62,65 % reduction in dry cough severity within 9 days.
76 % reduction in dry cough severity within 12 days
FREQUENCY
50 % reduction in dry cough frequency within 6 days.
80 % reduction in dry cough frequency within 12 days.
98 % reduction in dry cough frequency within 14 days.
THROAT IRRITATION
7,5 % reduction in throat irritation within 2 hours.
40 % reduction in throat irritation within 3 days.
60 % reduction in throat irritation within 6 days.
80 % reduction in throat irritation within 9 days.
90 % reduction in throat irritation within 12 days.
Throat irritation lower by 37,8 % within 3 days compare to the placebo group.
Throat irritation lower by 55,4 % within 6 days compare to the placebo group.
Throat irritation lower by 73,4 % within 9 days compare to the placebo group.
Throat irritation lower by 89,7 % within 12 days compare to the placebo group.
THROAT PAIN
19 % reduction in throat pain within 2 days.
38 % reduction in throat pain within 3 days.56 % reduction in throat pain within 6 days.
• 72 % reduction in throat pain within 9 days.
• 86 % reduction in throat pain within 12 days.
• 99 % reduction in throat pain within 14 days
| Indication | Filmogen liquid bandage for the treatment of cough. |
| Composition | Filmogenic glycerol, water, association of Hedera helix, Curcuma longa and EO : Eucalyptus globulus. |
| Presentation | Throat spray 30ml |
| Class | MDD Classe I | MDR Class IIa |
| Direction | Apply 2 sprays in throat, 2-3 times a day |
| Precautions | For topical use only (oral cavity). Keep out of reach and sight of children. |
| Age | 18+ |
| Storage conditions | Below 25°C |
| Legal manufacturer | VITROBIO (France) |
| Product code | CDN |